A5019952256- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Prostate Cancer Treatment and Research
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Neuropeptides and Animal Physiology
- Glioma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Immune cells in cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Prostate Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Cancer-related molecular mechanisms research
- CAR-T cell therapy research
- Sperm and Testicular Function
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Mast cells and histamine
Universidad de Navarra
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Clinica Universidad de Navarra
2009-2025
Navarre Institute of Health Research
2015-2025
Instituto de Salud Carlos III
2017-2025
Mount Sinai Health System
2023
Chartered Institute of Management Accountants
2010-2021
Complejo Asistencial Sótero del Río
1990-2020
Pontificia Universidad Católica de Chile
2019
University Hospital Complex Of Vigo
2004-2018
K-RAS is a highly relevant oncogene that mutated in approximately 90% of pancreatic cancers and 20-25% lung adenocarcinomas. The aim this work was to develop new anti-KRAS siRNA therapeutic strategy through the engineering functionalized lipid nanoparticles (LNPs). To do this, first, potent pan sequence chosen from literature different chemical modifications were tested for their transfection efficacy (KRAS knockdown) anti-proliferative effects on various cancer cell lines. Second, selected...
Background Tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of immune system to fight cancer and hinder antitumoral efficacy most treatments currently applied in clinic. Previous studies have evaluated response triggered by (TLR) agonists, such as poly(I:C), imiquimod (R837) or resiquimod (R848) monotherapies; however, their combination for treatment has not been explored. This study investigates macrophage reprogramming poly(I:C) combined with...
Abstract Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and associated toxicity have questioned clinical impact of this approach emphasized need alternative treatments. Given limited therapeutic options available these poor understanding molecular mechanisms underlying resistance metastatic lesions to WBRT, we sought uncover actionable targets biomarkers that could help refine patient...
Immunotherapy resistance in non-small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can shaped the mutational landscape of tumor. Here, we observed genetic alterations PTEN/PI3K/AKT/mTOR pathway and/or loss PTEN expression >25% patients with NSCLC, higher frequency squamous carcinomas (LUSC). Patients PTEN-low tumors had levels PD-L1 and PD-L2 showed worse progression-free survival when treated immunotherapy. Development a Pten-null LUSC mouse model...
Background In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits ability of immune system to fight cancer. Toll-like receptors (TLRs) ligands, such as poly(I:C) or resiquimod (R848) are able reprogram TAMs towards M1-like antitumor effector cells. The objective our work has been develop and evaluate polymeric nanocapsules (NCs) loaded with poly(I:C)+R848, improve drug stability systemic toxicity, their targeting therapeutic...
Abstract We explored the risk factors for gallbladder cancer and explanations its sharp constant incidence increase in Chile since 1970s. compared 114 consecutive patients with verified cancer, diagnosed 1992–1995, to matched hospital gallstones, using conditional logistic regression analysis. Low education showed a nonsignificant positive relationship [odds ratio (OR) = 2.3, 95% confidence interval (CI) 0.8–6.2], low socioeconomic level significant (OR 5.0, CI 1.5–17.3). A very long history...
Mortality rates for advanced lung cancer have not declined decades, even with the implementation of novel chemotherapeutic regimens or use tyrosine kinase inhibitors. Cancer Stem Cells (CSCs) are thought to be responsible resistance chemo/radiotherapy. Therefore, targeting CSCs compounds may an effective approach reduce tumor growth and metastasis. We isolated characterized from non-small cell (NSCLC) lines measured their telomerase activity, telomere length, sensitivity inhibitor MST312.The...
Cancer stem cells (CSCs) are thought to be responsible for tumor initiation and recurrence after chemotherapy. Targeting CSCs non-CSCs with specific compounds may an effective approach reduce lung cancer growth metastasis. The aim of this study was investigate the effect salinomycin, a selective inhibitor CSCs, or without combination paclitaxel, in metastatic model. To evaluate these drugs metastasis microenvironment we took advantage immunocompetent highly LLC mouse Aldefluor assays were...
To identify tissue microRNAs predictive of sunitinib activity in patients with metastatic renal-cell-carcinoma (MRCC) and to evaluate vitro their mechanism action resistance.We screened 673 using TaqMan Low-density-Arrays (TLDAs) tumors from MRCC extreme phenotypes marked efficacy resistance sunitinib, selected an identification cohort (n = 41). The most relevant differentially expressed were bioinformatics-based target prediction analysis quantified by qRT-PCR presenting similar independent...
Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non-small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers for successful therapies. Molecular YES1, a member the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found significant subset patients with cancer.Objectives: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) alteration as therapeutic target...
The use of immune-checkpoint inhibitors has drastically improved the management patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate immune cytotoxic activity, in combination antiprogrammed death 1 (PD-1) antibody, a great promise overcome resistance. We evaluated impact SRC family kinases (SFKs) on NSCLC prognosis, immunomodulatory effect SFK inhibitor dasatinib, anti-PD-1,...